According to the data, adverse events included growing hematomas, seizures, headaches, nausea, and myelosuppression.

Progression-free survival was roughly 162 days (5.4 months) in group A versus 237 days (7.9 months) in group B. In patients treated with bevacizumab alone, progression-free survival was roughly 120 days (4 months).


Continue Reading

Overall survival was 20.7 months in group A and 16.2 months in group B, which bypassed the average life expectancy for these patients.

Bruns and colleagues also sought to examine how carboplatin-based intra-arterial chemotherapy affected health-related quality of life. Patients had to have received and failed standard of care for glioblastoma. Those with bilateral disease, those who are immediately post-radiation, and those with comorbid conditions were excluded.

The study measured quality of life at baseline and 1, 2, and 4 months after therapy. The researchers have enrolled 20 patients to date, and 14 have currently completed a minimum of 4 months of treatment. During her presentation, Bruns discussed results of an interim analysis of these patients.

Patients were relatively younger, aged 34 to 67 years. Time since initial diagnosis ranged from 7 to 68 months. Adverse events included hematoma, a varicella outbreak related to myelosuppression, headaches, nausea, fatigue, which is an ongoing issue, and stroke in one patient.

Seven quality of life domains were examined, including global quality of life, role function, social function, visual disorder, motor dysfunction, communication deficit, and drowsiness.

RELATED: Brain Cancer Vaccine Offers New Proimse

Results revealed improvements in global quality of life, role function, and social function scores from baseline through follow-up, with the exception of social function at month 4. Visual disorder, motor dysfunction, communication deficit, and drowsiness typically decreased as time went by.

“Intra-arterial chemotherapy with carboplatin is relatively safe and well-tolerated. In this small study cohort, no major treatment-related adverse events occurred and we did not see any significant detrimental effects on quality of life scores in any of the seven preselected domains. Rather, there was an improvement in global quality of life and role function scores in the majority of patients,” Bruns concluded.

Reference

  1. Bruns P. Effect of intra-arterial chemotherapy treatment on health-related quality of life in patients with recurrent high-grade glioma. Presented at: Oncology Nursing Society (ONS) 39th Annual Congress; May 1-4, 2014; Anaheim, CA.

This article originally appeared on ONA